Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.38 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.38 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411907 | 0.82 | GSK3A (0.43) | GSK3BGSK3ACDK1CDK5CCNB2 | |
| SCHEMBL411503 | 0.81 | RPS6KA3 (0.39) | GSK3BCDK5CDK5R1RPS6KA3PDPK1 | |
| SCHEMBL10189779 | 0.79 | MAPK1 (0.34) | TNIKMAPK1MAP2K4MAPKAPK2MAPK6 | |
| SCHEMBL13041108 | 0.77 | KDR (0.52) | MAPK1CDK2KDRMEN1MAPT | |
| SCHEMBL13078074 | 0.77 | HSD17B1 (0.39) | GSK3BGSK3ACDK1CDK5CCNB2 | |
| SCHEMBL10189713 | 0.75 | MAPT (0.42) | MAPK1MAP2K4MEN1NPC1MAPT | |
| SCHEMBL10189699 | 0.75 | ALDH1A1 (0.35) | GSK3BGSK3ACDK1CDK5CCNB2 | |
| SCHEMBL10189728 | 0.75 | SMPD3 (0.41) | GSK3BGSK3ACDK1CDK5CCNB2 | |
| SCHEMBL10189720 | 0.74 | TUBB1 (0.44) | MAPK1CDK2KDRMEN1MAPT | |
| SCHEMBL10189751 | 0.74 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | GSK3B 239/4885GSK3A 416/4885CDK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.